sb 203580 has been researched along with 4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine) | Trials (4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine) | Recent Studies (post-2010) (4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 13 | 0 | 12 |
| Protein | Taxonomy | sb 203580 (IC50) | 4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine (IC50) |
|---|---|---|---|
| Chain A, Casein kinase I isoform delta | Homo sapiens (human) | 0.014 | |
| Chain A, Casein kinase I isoform delta | Homo sapiens (human) | 0.013 | |
| Chain A, Casein kinase I isoform epsilon | Homo sapiens (human) | 0.013 | |
| Mitogen-activated protein kinase 13 | Homo sapiens (human) | 0.0392 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.15 | |
| Gonadotropin-releasing hormone receptor | Homo sapiens (human) | 0.13 | |
| Casein kinase I isoform delta | Homo sapiens (human) | 0.031 | |
| Casein kinase I isoform epsilon | Homo sapiens (human) | 0.0524 | |
| Mitogen-activated protein kinase 12 | Homo sapiens (human) | 0.0392 | |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | 0.0392 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.1146 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Munoz, L | 1 |
1 review(s) available for sb 203580 and 4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine
| Article | Year |
|---|---|
Non-kinase targets of protein kinase inhibitors.
Topics: Animals; Drug Design; Drug Evaluation, Preclinical; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Kinases | 2017 |